We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Global In Vitro Diagnostics Market to Reach USD 90 Billion by 2025

By LabMedica International staff writers
Posted on 07 Feb 2019
The global in vitro diagnostics market was valued at USD 55.00 billion in 2016 and is projected to grow at a healthy CAGR of 5.60% between 2017 and 2025 to reach USD 89.8 billion by the end of 2025. More...
The market growth will be driven by the rising prevalence of chronic diseases worldwide, an increase in the number of public and private diagnostic centers due to growing awareness of various diseases among the people, and an increasingly health conscious population who prefer early treatment. Additionally, the aggressive growth in the health sector and rapid technological advancements are helping to create better and more efficient products, thereby further aiding the market growth.

These are the latest findings of Transparency Market Research, (Albany, NY, USA), a global market intelligence company providing business information reports and services.

Increasing incidences of chronic diseases such as cancer, tuberculosis, diabetes, and cardiovascular diseases are likely to drive the growth of the global in vitro diagnostics market over the coming years. Additionally, a surge in the number of patients suffering from infectious diseases, such as sexually transmitted diseases (STDs), respiratory, and gastrointestinal, are expected to further boost the demand in the market. A sharp increase in cardiovascular diseases and diabetes, particularly in the developed countries, has helped the in vitro diagnostic market grow at a stupendous pace. Moreover, an increase in the geriatric population is also fueling market demand as the elderly people are more vulnerable to diseases due to their low immunity, thereby boosting the overall healthcare industry and resulting in the huge growth of the vitro diagnostic market.

The healthcare industry has been witnessing tremendous development and is expected to continue growing during the forecasts period on the back of the advent of personalized medicines and rise in the uptake of automated instruments. Earlier, in vitro diagnostics used to be performed only in labs, but can now be quickly and accurately carried out at home without the presence of any skilled professionals. One can test for pregnancy, blood glucose levels and even diseases such as HIV at home without visiting a diagnostic center, resulting in reduced hospital bills and increasing convenience. Such devices have gained immense popularity among the people due to their user-friendly nature, thus further boosting the growth of the in vitro diagnostics market. However, frequent regulatory changes and the lack of favorable reimbursement facilities for in vitro diagnostic are likely to hamper the market growth.

Currently, the global in vitro diagnostics market is highly competitive with a large number of players operating worldwide. The increasing emphasis of the key players on research and development, coupled with the introduction of new technology, is expected to support the market growth over the next few years. Additionally, increasing mergers and acquisition are likely to help the leading players maintain their position and increase market penetration in the coming years.

Related Links:
Transparency Market Research

New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.